Top in GI: AGA guidance, refractory UC treatment

The American Gastroenterological Association released new guidance that recommends using bidirectional endoscopy to evaluate iron deficiency anemia. It was the top story in gastroenterology last week.

Another top story was about new data that showed a once-daily treatment for ulcerative colitis was effective for up to 2 years of therapy.

Read these and more top stories in gastroenterology below:

AGA recommends bidirectional endoscopy to evaluate iron deficiency anemia

The American Gastroenterological Association recently published clinical guidelines for gastrointestinal evaluation of iron deficiency anemia in Gastroenterology. Read more.

Oral drug shows efficacy up to 2 years in refractory UC

ABX464, a once-daily, oral treatment for ulcerative colitis, showed efficacy for up to 2 years of therapy in a phase 2a trial, according to the drug’s manufacturer Abivax. Read more.

Seven recent reports in interventional endoscopy

Healio presents recent reports on some of the most recent developments on balloon-assisted enteroscopy, the current state of endoscopic education and how doctors across the country worked toward reopening their endoscopy centers in the wake of the COVID-19 pandemic. Read more.

VIDEO: No ‘hard-to-reach’ patients in HCV, just ‘hardly reached’

In this video, Joss O’Loan, MBBS, from the Hepatitis C Kombi Clinic in Brisbane, Australia, discusses two studies presented at The Digital International Liver Congress on HCV elimination programs using Epclusa (sofosbuvir/velpatasvir, Gilead Sciences). Read more.

HBV drug well tolerated, reduces surface antigens in phase 2 trial

Patients with hepatitis B treated with an investigational RNAi drug experienced reduced levels of surface antigens across different dose levels, according to research presented at The Digital International Liver Congress. Read more.